Lupeol targets liver tumor‐initiating cells through phosphatase and tensin homolog modulation

Liver tumor‐initiating cells (T‐ICs) are capable of self‐renewal and tumor initiation and are more chemoresistant to chemotherapeutic drugs. The current therapeutic strategies for targeting stem cell self‐renewal pathways therefore represent rational approaches for cancer prevention and treatment. In the present study, we found that Lup‐20(29)‐en‐3β‐ol (lupeol), a triterpene found in fruits and vegetables, inhibited the self‐renewal ability of liver T‐ICs present in both hepatocellular carcinoma (HCC) cell lines and clinical HCC samples, as reflected by hepatosphere formation. Furthermore, lupeol inhibited in vivo tumorigenicity in nude mice and down‐regulated CD133 expression, which was previously shown to be a T‐IC marker for HCC. In addition, lupeol sensitized HCC cells to chemotherapeutic agents through the phosphatase and tensin homolog (PTEN)–Akt–ABCG2 pathway. PTEN plays a crucial role in the self‐renewal and chemoresistance of liver T‐ICs; down‐regulation of PTEN by a lentiviral‐based approach reversed the effect of lupeol on liver T‐ICs. Using an in vivo chemoresistant HCC tumor model, lupeol dramatically decreased the tumor volumes of MHCC‐LM3 HCC cell line‐derived xenografts, and the effect was equivalent to that of combined cisplatin and doxorubicin treatment. Lupeol exerted a synergistic effect without any adverse effects on body weight when combined with chemotherapeutic drugs. Conclusion: Our results suggest that lupeol may be an effective dietary phytochemical that targets liver T‐ICs. (HEPATOLOGY 2011.)

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[3]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[4]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[5]  B. Stiles,et al.  Expansion of CD133‐Expressing Liver Cancer Stem Cells in Liver‐Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10‐Deleted Mice , 2009, Stem cells.

[6]  M. Inoue,et al.  Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan , 2009, British Journal of Cancer.

[7]  Shusen Zheng,et al.  Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. , 2008, Carcinogenesis.

[8]  H. Taniguchi,et al.  Stem Cells and Cancer in the Liver , 2008, Disease markers.

[9]  Jiang Zhu,et al.  Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials , 2008, Journal of Cancer Research and Clinical Oncology.

[10]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[11]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[12]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[13]  Xin Wei Wang,et al.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.

[14]  P. Altevogt,et al.  Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. , 2007, Cancer research.

[15]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[16]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[17]  K. Sabapathy,et al.  c-Jun promotes cellular survival by suppression of PTEN , 2007, Cell Death and Differentiation.

[18]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[19]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[20]  M. Bartels,et al.  Liver resection and transplantation in the management of hepatocellular carcinoma: a review. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[21]  W. Hahn,et al.  Roots and stems: stem cells in cancer , 2006, Nature Medicine.

[22]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[23]  E. Tokunaga,et al.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer , 2005, International journal of cancer.

[24]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[25]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[26]  G. Dontu,et al.  Mammary stem cells, self-renewal pathways, and carcinogenesis , 2005, Breast Cancer Research.

[27]  B. Carr,et al.  Hepatocellular carcinoma: current management and future trends. , 2004, Gastroenterology.

[28]  V. Adhami,et al.  Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice , 2004, Oncogene.

[29]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[30]  K. Hashimoto,et al.  Regulation of constitutive expression of mouse PTEN by the 5′-untranslated region , 2003, Oncogene.

[31]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[33]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[34]  D. Ota,et al.  Radiofrequency ablation of liver tumors: influence of technique and tumor size. , 2002, Surgery.

[35]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[36]  J. Roy-Chowdhury,et al.  A long‐term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag‐2–deficient mice , 2000, Hepatology.

[37]  P. Kerbrat,et al.  [Nonsurgical treatment of hepatocellular carcinoma]. , 1999, Bulletin du cancer.

[38]  C. la Vecchia,et al.  Attributable risks for hepatocellular carcinoma in northern Italy. , 1997, European journal of cancer.